Skip to Main Content

Gilead Sciences said Thursday that it has exercised an option to license four cancer drugs from Arcus Biosciences, including an immunotherapy that works against a closely followed anti-cancer target called TIGIT.

In exchange for licensing rights to the four cancer drugs, Gilead is paying Arcus $725 million. The two companies will co-develop the drugs, share costs, and if approved, split profits in the U.S., the companies said.


For Gilead, the Arcus deal represents another potentially lucrative but risky effort to grow its cancer business, which has struggled to gain traction apart from its bespoke CAR-T therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.